advent
modern
microbiolog
streptococcu
pneumonia
pneumococcu
identifi
caus
communityacquir
pneumonia
cap
patient
case
fatal
rate
cfr
untreat
bacterem
pneumococc
pneumonia
earli
studi
defin
import
opson
antibodi
infect
serotyp
serum
therapi
institut
result
decreas
cfr
advent
antimicrobi
therapi
cfr
bacterem
pneumococc
diseas
decreas
chang
pattern
pneumococc
pneumonia
recogn
next
year
even
though
pneumococcu
remain
suscept
penicillin
cfr
remain
constant
modern
icu
fail
improv
cfr
complic
matter
pneumonia
strain
develop
resist
penicillin
antimicrobi
agent
use
treat
pneumonia
sever
retrospect
studi
suggest
combin
therapi
blactam
macrolid
antimicrobi
agent
result
lower
cfr
therapi
blactam
alon
articl
address
avail
data
treatment
bacterem
pneumococc
pneumonia
discuss
biolog
feasibl
explan
behind
new
therapi
guidelin
treatment
clinic
syndrom
cap
publish
sever
pulmonari
infecti
diseas
societi
guidelin
address
detail
articl
issu
evalu
bacterem
pneumococc
pneumonia
seri
cap
case
examin
physician
infrequ
know
whether
patient
pneumococc
pneumonia
initi
present
year
mani
seri
cap
case
publish
reflect
chang
natur
cap
seri
cap
pneumonia
predomin
pathogen
account
case
subsequ
decad
anoth
pathogen
group
pathogen
identifi
caus
cap
mycoplasma
pneumonia
identifi
initi
caus
atyp
pneumonia
import
anaerob
organ
aspir
pneumonia
identifi
legionella
pneumophila
discov
caus
epidem
legionnair
diseas
chlamydia
pneumonia
identifi
anoth
caus
atyp
pneumonia
import
atyp
viral
caus
cap
adult
ie
respiratori
syncyti
viru
parainfluenza
hantaviru
metapneumonia
viru
coronaviru
sever
acut
respiratori
syndrom
identifi
variou
investig
includ
center
diseas
control
prevent
world
health
organ
recent
seri
abl
identifi
pneumonia
patient
cap
specif
caus
found
patient
approxim
one
third
patient
taken
least
one
dose
antibiot
present
physician
servic
mani
microbiolog
laboratori
scale
back
hospit
budgetari
constraint
consolid
mani
hospit
led
use
central
refer
laboratori
prolong
time
specimen
collect
process
factor
decreas
abil
cultur
pyogen
organ
pneumonia
center
use
method
addit
cultur
pneumonia
antigen
detect
serolog
mean
report
find
case
pneumococc
pneumonia
case
pneumonia
caus
unidentifi
pathogen
suggest
mani
patient
without
defin
caus
pneumococc
pneumonia
patient
increas
suscept
pneumococcu
may
suscept
pulmonari
pathogen
lead
dual
infect
pathogen
influenza
viru
render
host
suscept
pneumococcu
predisposit
pneumococc
infect
may
hold
true
patient
anteced
pneumonia
c
pneumonia
infect
lesson
learn
seri
patient
cap
includ
fact
may
difficult
identifi
case
pneumococc
pneumonia
patient
pneumococc
pneumonia
may
addit
infect
patient
pneumonia
reflect
demograph
chang
us
popul
studi
pneumococc
bacteremia
suggest
incid
diseas
increas
us
popul
pathophysiolog
pneumonia
acquir
inhal
larg
droplet
carrier
pneumococcu
must
colon
oropharyng
epitheli
cell
abl
multipli
microaspir
organ
lung
caus
pneumonia
effici
process
low
instanc
patient
pneumococc
pneumonia
place
respiratori
isol
certain
close
popul
jail
longterm
care
facil
day
care
center
process
effici
higher
outbreak
occur
defens
system
host
help
control
pneumonia
attach
conjug
vaccin
growth
spread
lung
factor
inhibit
ciliari
function
smoke
viral
infect
increas
likelihood
acquir
pneumococc
pneumonia
pulmonari
parenchyma
pneumococcu
elicit
intens
inflammatori
reaction
phagocytosi
enhanc
typespecif
opson
antibodi
present
bacteremia
like
occur
absenc
antibodi
hypogammaglobulinemia
diminish
function
phagocyt
cell
alcohol
decreas
inflammatori
respons
complement
defici
absenc
clear
function
spleen
sickl
cell
diseas
splenectomi
earli
pneumonia
isol
suscept
antimicrobi
agent
use
treat
respiratori
infect
sinc
higher
concentr
penicillin
requir
inhibit
growth
pneumococcu
chang
suscept
antimicrobi
agent
discuss
detail
anoth
articl
issu
gener
blactam
antibiot
effect
treat
nonmening
ie
pneumonia
bacteremia
pneumococc
diseas
case
although
sever
respiratori
pathogen
may
higher
cfr
rate
pseudomona
aeruginosa
pneumonia
total
number
caprel
death
caus
pneumococci
exce
number
death
caus
pathogen
seem
logic
chang
treatment
cap
result
favor
outcom
also
would
benefici
patient
pneumococc
pneumonia
chang
associ
improv
cfr
seri
patient
cap
includ
rapid
antibiot
deliveri
combin
therapi
cephalosporin
good
pneumococc
activ
macrolid
versu
cephalosporin
alon
therapi
fluoroquinolon
ciprofloxacin
versu
cephalosporin
alon
cultur
pneumonia
normal
steril
bodi
fluid
blood
pleural
fluid
patient
acut
pneumonia
usual
accept
definit
sign
pneumococc
pneumonia
debat
valu
cultur
pneumonia
expector
sputum
even
compat
gram
stain
although
clinician
experi
pneumococc
pneumonia
valu
inform
provid
highqual
pulmonari
secret
rapid
pneumonia
urinari
antigen
evalu
shown
good
specif
adult
popul
studi
reason
sensit
studi
test
sensit
heavili
colon
children
could
discrimin
among
infect
colon
children
underdevelop
countri
studi
spain
studi
patient
hospit
acut
cap
pneumonia
urinari
antigen
spua
test
perform
pneumococci
found
cultur
patient
half
blood
half
sputum
spua
test
posit
patient
posit
cultur
howev
addit
patient
posit
spua
test
cultur
neg
pneumococcu
specif
report
greater
adult
patient
also
pneumococc
pneumonia
studi
patient
would
pneumococc
pneumonia
proport
pneumococc
pneumonia
case
similar
proport
larg
seri
hospit
case
cap
sensit
spua
test
would
patient
least
would
four
time
greater
combin
cultur
sputum
blood
patient
cultur
still
would
import
determin
antimicrobi
suscept
sever
retrospect
studi
suggest
monotherapi
effect
cephalosporin
adequ
treatment
pneumococc
pneumonia
mufson
stanek
report
patient
pneumococc
bacteremia
huntington
west
virginia
year
data
analyz
period
overal
incid
pneumococcal
bacteremia
increas
cfr
decreas
period
regimen
includ
macrolid
blactam
result
lower
cfr
regimen
involv
blactam
alon
two
antibiot
exclud
macrolid
specif
provid
time
initi
dose
chang
therapi
fluoroquinolon
use
infrequ
although
studi
retrospect
control
sever
ill
may
offer
first
clue
monotherapi
pneumococc
bacteremia
cephalosporin
less
efficaci
combin
therapi
cephalosporin
macrolid
water
et
al
report
data
antimicrobi
therapi
patient
bacterem
pneumococc
pneumonia
hospit
tennesse
januari
juli
immunecompromis
patient
exclud
seven
patient
pneumonia
isol
resist
empir
therapi
also
exclud
patient
receiv
one
antibiot
activ
patient
isol
singl
effect
therapi
set
two
effect
antibiot
dual
effect
therapi
det
two
effect
antibiot
met
logist
regress
analysi
use
calcul
odd
ratio
death
adjust
predict
mortal
compar
det
set
confid
interv
ci
death
occur
case
pneumonia
sever
index
psi
class
iv
v
even
exclud
death
occur
first
hour
hospit
set
independ
predictor
death
ci
analysi
done
evalu
coverag
atyp
pathogen
cfr
patient
patient
receiv
atyp
coverag
patient
receiv
atyp
coverag
howev
predict
mortal
rate
higher
latter
group
patient
multivari
analysi
show
lack
atyp
coverag
predictor
death
p
investig
suggest
prospect
studi
address
set
versu
det
patient
pneumococc
bacteremia
psi
class
iv
v
state
pneumonia
urinari
antigen
help
rapidli
identifi
subset
patient
pneumococc
pneumonia
martinez
et
al
perform
retrospect
analysi
databas
patient
bacterem
pneumococc
pneumonia
patient
analyz
receiv
empir
therapi
blactam
plu
macrolid
wherea
receiv
empir
therapi
blactam
alon
potenti
risk
factor
inhospit
death
identifi
stepwis
logist
regress
analysi
multivari
analysi
reveal
absenc
macrolid
initi
empir
regimen
independ
associ
death
p
independ
predictor
death
includ
shock
age
greater
year
blood
cultur
isol
pneumonia
strain
resist
penicillin
erythromycin
total
patient
die
even
data
reanalyz
exclud
earli
death
occur
hour
present
absenc
macrolid
initi
therapi
associ
death
ci
studi
macrolid
could
combin
favor
cephalosporin
blactamas
inhibitor
previou
studi
patient
cap
nonbacterem
pneumococc
pneumonia
found
treat
blactamas
inhibitor
macrolid
less
effect
treatment
cephalosporin
alon
retrospect
studi
differ
among
popuat
group
receiv
cephalosporin
alon
higher
incid
comorbid
condit
hiv
infect
hematolog
malign
neutropenia
nosocomi
bacteremia
penicillinresist
isol
group
receiv
blactamas
inhibitor
macrolid
patient
experienc
shock
result
admiss
icu
investig
caution
prospect
random
trial
necessari
definit
determin
effect
macrolid
bacterem
pneumococc
pneumonia
remain
seriou
lifethreaten
infect
incid
pneumococc
bacteremia
seem
increas
cfr
bacterem
pneumococc
pneumonia
chang
much
past
year
alway
unansw
question
regard
sever
pneumococc
diseas
cfr
differ
among
differ
center
countri
countri
mani
case
nosocomi
pneumonia
infect
other
eg
unit
state
minim
number
case
report
suggest
combin
antimicrobi
therapi
contain
macrolid
effect
therapi
cephalosporin
blactam
alon
articl
address
publish
literatur
would
blactam
cephalosporin
combin
macrolid
efficaci
blactam
cephalosporin
alon
treatment
patient
bacterem
pneumococc
pneumonia
interact
two
antibiot
streptococcu
pneumonia
although
antibiot
combin
shown
synergist
vitro
vivo
ie
ampicillin
gentamicin
enterococci
data
suggest
synergist
activ
exist
cephalosporin
penicillin
macrolid
pneumococci
evid
combin
penicillin
tetracyclin
antagonist
effect
patient
pneumococc
mening
one
possibl
explan
decreas
mortal
rate
combin
therapi
could
macrolid
somewhat
antagonist
rapid
kill
pneumococci
cephalosporin
effect
could
slow
rapid
lysi
pneumococci
abat
result
intens
inflammatori
respons
would
use
two
empir
antibiot
make
like
least
one
would
activ
pneumococcu
studi
water
et
al
exclud
organ
resist
empir
therapi
still
demonstr
benefit
macrolid
use
lujan
et
al
demonstr
discord
therapi
associ
higher
cfr
find
seen
among
physician
use
thirdgener
cephalosporin
pneumococc
resist
ceftriaxon
cefotaxim
minim
patient
possibl
macrolid
treat
secondari
infect
patient
pneumococc
bacteremia
influenza
infect
predispos
pneumococc
pneumonia
bacteremia
sever
mechan
coinfect
atyp
pathogen
would
resist
cephalosporin
suscept
macrolid
includ
pneumonia
c
pneumonia
describ
clear
whether
patient
dual
infect
fare
wors
pneumococc
bacteremia
treat
coinfect
pneumonia
l
pneumophila
describ
epidemiolog
studi
cap
etiolog
agent
identifi
larg
proport
patient
possibl
pulmonari
pathogen
suscept
macrolid
identifi
mcnalli
et
al
screen
acut
convalesc
serum
sampl
patient
pneumonia
unknown
caus
legionella
bozemanii
identifi
potenti
caus
case
use
criterion
fourfold
rise
antibodi
titer
acut
convalesc
sampl
possibl
legionella
legionellalik
organ
requir
differ
growth
medium
identifi
possibl
immunemodul
activ
macrolid
import
reduc
mortal
rate
intens
host
inflammatori
respons
sepsi
sometim
deleteri
multipl
studi
use
differ
agent
tri
diminish
exagger
immun
respons
steroid
studi
multipl
dose
mani
studi
success
difficult
demonstr
patient
sepsi
given
antibiot
howev
steroid
seem
help
reduc
morbid
rate
patient
bacteri
mening
studi
patient
difficult
sepsi
variou
stage
ill
treat
antibodi
endotoxin
tumor
necrosi
factor
tnf
differ
result
one
murin
studi
show
antibodi
tnf
deleteri
effect
mice
pneumococc
pneumonia
also
treat
ceftriaxon
review
human
trial
antibodi
tnf
show
effect
mortal
rate
patient
sever
sepsi
bacteri
pneumonia
compon
complex
inflammatori
respons
granulocyt
colonystimul
factor
gcsf
investig
mice
human
local
product
gcsf
seem
occur
site
infect
patient
unilater
pneumonia
macrolid
shown
inhibit
variou
factor
inflammatori
respons
mostli
mice
human
studi
shown
immunemodul
activ
macrolid
benefici
effect
investig
complex
immun
respons
saluatori
deleteri
effect
mortal
rate
import
larg
number
articl
address
issu
vivo
suscept
data
erythromycin
macrolid
correl
clinic
outcom
retrospect
studi
spain
examin
patient
admit
cap
treat
combin
therapi
patient
receiv
ceftriaxon
type
macrolid
therapi
chosen
attend
physician
choic
mg
oral
azithromycin
daili
day
n
mg
intraven
clarithromycin
twice
daili
switch
oral
treatment
total
durat
treatment
day
n
patient
similar
age
comorbid
psi
length
stay
lo
azithromycin
group
day
shorter
p
cfr
azithromycin
group
clarithromycin
group
p
obviou
reason
differ
two
treatment
arm
investig
suggest
complianc
might
issu
patient
azithromycin
arm
receiv
cours
hospit
wherea
mani
patient
clarithromycin
arm
complet
cours
home
possibl
includ
differ
antiinflammatori
attribut
two
drug
presenc
unknown
pathogen
suscept
azithromycin
resist
clarithromycin
analysi
retrospect
analysi
may
undiscov
bias
need
futur
retrospect
studi
discuss
earlier
suggest
combin
therapi
better
cephalosporin
monotherapi
elderli
patient
cap
older
sicker
patient
bacteremia
pneumococc
pneumonia
caution
overinterpret
retrospect
studi
publish
investig
inflammatori
respons
patient
sever
pneumococc
pneumonia
incorpor
recent
advanc
murin
studi
prospect
studi
aim
test
avail
hypothes
need
develop
pneumonia
urinari
antigen
help
defin
subset
patient
studi
intens
test
need
assess
inflammatori
respons
resolut
ill
ie
rapid
reduct
magnitud
bacteremia
import
altern
pathogen
pneumonia
c
pneumonia
l
pneumophila
legionella
spp
virus
variabl
taken
account
includ
specif
macrolid
use
effect
class
antimicrobi
agent
fluoroquinolon
ideal
studi
would
includ
provis
autopsi
postmortem
pulmonari
biopsi
fatal
case
studi
design
perform
vigil
need
immun
appropri
patient
influenza
pneumococc
vaccin
prevent
bacterem
pneumococc
pneumonia
